EUVIMEDEUVIMED entdecken
Crossref

Association of Countries’ Atopic Dermatitis Burden and Sociodemographic Index with Topical Calcineurin Inhibitor Utilization

Inna Ushcatz iD, Heather J Zhao, Mina Tadrous, Valeria Aoki, Aileen Y Chang, Ncoza Dlova, Arbie Sofia P Merilleno, Aaron M Drucker

Dermatitis® · 2025

DOI: 10.1089/derm.2024.0107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatitis®, 2025. Verfasst von Inna Ushcatz und 7 weiteren Autor:innen. Beteiligte Einrichtung: From the Women's College Research Institute and Department of Medicine, Women's College Hospital, Toronto, Canada. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Calcineurin Inhibitors, Drug Utilization. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is limited knowledge on international trends in topical calcineurin inhibitor (TCI) utilization.

Objective

To describe international TCI utilization trends from 2012 to 2019 and evaluate the relationship of country-level economic status, geographic location, and atopic dermatitis (AD) disease burden with drug utilization.

Methods

We used IQVIA MIDAS® pharmaceutical quarterly sales data to attain country-level purchasing of TCIs in grams from 2012 to 2019. A multivariable linear regression estimated the association between countries' sociodemographic index (SDI), AD disability-adjusted life year (DALY) rates, and geographic location with TCI utilization.

Results

A total of 68 countries were included in our analysis. From 2012 to 2019, overall TCI utilization increased by 66% but remained 11.2 times higher in high-sociodemographic compared with low-middle/low-sociodemographic countries. SDI and geographic location were associated with greater TCI utilization in multivariable analyses, whereas AD DALY rates were not. High-SDI countries used 21,476 grams (95% confidence interval [CI]: 11,915 to 31,036) and high-middle SDI countries used 9,403 grams (95% CI: -393 to 19,200) more TCIs per 100,000 people compared with low-middle/low-SDI countries, respectively. Northern hemisphere countries used 8,588 grams more TCIs per 100,000 people (95% CI: 612 to 16,564).

Conclusions

We demonstrated greater TCI utilization among high-SDI compared with lower SDI countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicCalcineurin InhibitorsDrug UtilizationHumansAdministration, TopicalDisability-Adjusted Life YearsSociodemographic FactorsSocioeconomic FactorsCost of Illness

Substanzen

Calcineurin Inhibitors

Autor:innen und Institutionen

  • From the Women's College Research Institute and Department of Medicine, Women's College Hospital, Toronto, Canada.
  • Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
  • Department of Dermatology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
  • Department of Dermatology, University of California School of Medicine, San Francisco, California, USA.
  • Department of Dermatology, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, USA.

ORCID-Profile: Inna Ushcatz

Zitieren

APA

Ushcatz, I., Zhao, H. J., Tadrous, M., Aoki, V., Chang, A. Y., Dlova, N., Merilleno, A. S. P., & Drucker, A. M. (2025). Association of Countries’ Atopic Dermatitis Burden and Sociodemographic Index with Topical Calcineurin Inhibitor Utilization. Dermatitis®. https://doi.org/10.1089/derm.2024.0107

Vancouver

Ushcatz I, Zhao HJ, Tadrous M, Aoki V, Chang AY, Dlova N, et al. Association of Countries’ Atopic Dermatitis Burden and Sociodemographic Index with Topical Calcineurin Inhibitor Utilization. Dermatitis®. 2025. doi:10.1089/derm.2024.0107

BibTeX
@article{Ushcatz2025,
  author = {Ushcatz, Inna and Zhao, Heather J and Tadrous, Mina and Aoki, Valeria and Chang, Aileen Y and Dlova, Ncoza and Merilleno, Arbie Sofia P and Drucker, Aaron M},
  title = {Association of Countries’ Atopic Dermatitis Burden and Sociodemographic Index with Topical Calcineurin Inhibitor Utilization},
  journal = {Dermatitis®},
  year = {2025},
  doi = {10.1089/derm.2024.0107}
}
Kostenlos starten →